Who are n-3 PUFAs's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Epanova, TRIGEL, Omacor + simvastatin, Omega-3 supplement, Trimetazidine mimic, fenofibrate/omega.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/n-3-pufas.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

n-3 PUFAs — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

n-3 PUFAs (n-3 PUFAs) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fatty acid. Area: Cardiovascular.

phase 3 Fatty acid Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

n-3 PUFAs (n-3 PUFAs) — Università degli Studi di Brescia. n-3 PUFAs are a class of fatty acids that exert anti-inflammatory effects and improve cardiovascular health.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
n-3 PUFAs TARGET	n-3 PUFAs	Università degli Studi di Brescia	phase 3	Fatty acid
Epanova	OMEGA-3-CARBOXYLIC ACIDS	AstraZeneca	marketed	Omega-3 Fatty Acid		2014-01-01
TRIGEL	TRIGEL	LobSor Pharmaceuticals AB	marketed	Fatty acid synthase inhibitor	Fatty acid synthase
Omacor + simvastatin	Omacor + simvastatin	Provident Clinical Research	marketed	Omega-3 fatty acid + HMG-CoA reductase inhibitor (statin)	VLDL production pathway (Omacor); HMG-CoA reductase (simvastatin)
Omega-3 supplement	Omega-3 supplement	Washington University School of Medicine	marketed	Dietary supplement / Fatty acid
Trimetazidine mimic	Trimetazidine mimic	Shenyang Northern Hospital	marketed	Metabolic modulator; fatty acid oxidation inhibitor	LC3KAT (long-chain 3-ketoacyl-CoA thiolase)
fenofibrate/omega	fenofibrate/omega	Gachon University Gil Medical Center	marketed	Fibrate + omega-3 fatty acid combination	PPARα (peroxisome proliferator-activated receptor alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fatty acid class)

Brigham and Women's Hospital · 1 drug in this class
Federal University of São Paulo · 1 drug in this class
McGill University Health Centre/Research Institute of the McGill University Health Centre · 1 drug in this class
Università degli Studi di Brescia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). n-3 PUFAs — Competitive Intelligence Brief. https://druglandscape.com/ci/n-3-pufas. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing